Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland
ConclusionRIV + ASA was a cost-effective treatment alternative compared with ASA in patients with CCS or symptomatic PAD in Finland.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Bleeding | Cardiology | Cardiovascular | Drugs & Pharmacology | Finland Health | Heart | Hemorrhagic Stroke | Ischemic Stroke | Peripheral Vascular Disease (PVD) | Stroke | Thrombosis